Review Article
Biomaterial Applications in Cell-Based Therapy in Experimental Stroke
Table 1
Examples of biomaterials applications in experimental stroke.
| Cells/growth factors | Species/stroke model | Biomaterial | Outcomes | References |
|
hRecombinant osteopontin | Rats tMCAO | Gelatin type A microspheres | of infarct volume neurological deficits | Jin et al. 2014 [122] |
| rBMSCs | Rats pMCAO | N-Isopropyl- acrylamide polymer sheets | Improvement of motor function | Ito et al. 2014 [87] |
| Pegylated EGF and EPO | Mice focal ischemia endothelin-1 | PEG microparticles PLGA nanoparticles dispersed in a (HAMC) hydrogel | ↓ of inflammation, ↓ of infarct volume | Wang et al. 2013 [99] |
| hNSC | Rats tMCAO | VEGF-PLGA microparticles | Neovascularization, angiogenesis | Bible et al. 2012 [123] |
| iPS-NPCs | Mice cortical photothrombotic | HA, acrylate | ↑ of differentiation to neuroblast | Lam et al. 2014 [95] |
| hNSC | Rats tMCAO | Xenogeneic (ECM) bioscaffold | Formation of de novo tissue | Bible et al. 2012 [121] |
| ONO-1301 | Rats tMCAO | Subcutaneous (PLGA) microspheres | Neuroprotection and ↓ side effects compared to OA | Hazekawa et al. 2012 [81] |
| HMGB1 | Rats tMCAO | Gelatin microspheres | ↓ infarct volume | Jin et al. 2011 [124] |
| EGF | Mice focal ischemia endothelin-1 | PEG microparticles dispersed in a (HAMC) hydrogel | ↑ neural stem/progenitor cells | Cooke et al. 2011 [125] |
| NSC | Rats tMCAO | Collagen type I matrix | ↑ synapses and functional recovery | Yu et al. 2010 [57] |
| hVEGF | Rats tMCAO | Alginate hydrogel | ↓ infarct volume ↓ functional deficits | Emerich et al. 2010 [55] |
|
|
MCAo p or t, permanent or transient middle cerebral artery occlusion; BMSCs, bone marrow stromal cells; EGF, epidermal growth factor; EPO, erythropoietin; SC, stem cells; PEG, polyethylene glycol; HAMC, hyaluronan methylcellulose; h, human; NSC, neural stem cells; VEGF, vascular endothelial growth factor, iPS, induced pluripotent stem; HA, hyaluronic acid; NPCs, neural pluripotent cells; PLGA, poly lactic-co-glycolic acid; OA, oral administration; HMGB1, high-mobility group box 1 protein; ECM, extracellular matrix.
|